Guggenheim raises target for Natera stock to USD 475

Published on 10/06/2026 at 11:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Natera revenue hit USD 752.75 million in Q2 2026, up 37.70 percent. Natera stock costs EUR 380.65 on October 6, 2026 versus EUR 379.25.

NTRA, US6323071042, Illustration mit AI erstellt.

Natera (ISIN US6323071042) was trading at EUR 380.65 at Lang & Schwarz on October 6, 2026 at 11:31 a.m. CEST, at plus 0.37 percent versus the prior close of EUR 379.25. According to Markets Insider on October 1, 2026, Guggenheim raised its Natera price target from USD 360.00 to USD 475.00 and kept a Buy rating.

Guggenheim lifts its target

The target increase came ahead of the third-quarter earnings season for diagnostics and life science tools companies. It gives the latest analyst view a more bullish level than the current consensus target of USD 341.55 cited by MarketBeat in its October 2, 2026 coverage.

That contrast matters because the target change followed a sharp repricing of Natera's growth story. MarketBeat reported that Natera shares had traded at USD 410.35 near the USD 427.47 52-week high on October 2, 2026, while the Lang & Schwarz quote now provides the German investor reference in euros.

Japan expands Signatera's runway

Natera's most concrete operating development is regulatory rather than financial. In a release dated September 22, 2026, Natera said Japan's Pharmaceuticals and Medical Devices Agency approved Signatera as a companion diagnostic for muscle-invasive bladder cancer.

The company said the indication supports treatment decisions involving adjuvant atezolizumab and that a commercial launch is expected in the first half of 2027, pending final reimbursement and pricing. Natera described the decision as its second PMDA authorization for Signatera in Japan, after a colorectal cancer approval in June 2026.

Revenue growth meets a loss

Natera generated USD 752.75 million of revenue in the second quarter of 2026, according to MarketBeat's October 2, 2026 report, which said quarterly revenue rose 37.70 percent year over year and exceeded the USD 661.24 million consensus estimate. The same report put adjusted earnings per share at negative USD 0.47 versus a negative USD 0.49 consensus estimate.

The operating picture is therefore mixed in a precise way: growth is running ahead of expectations, while profitability remains negative. Finance data for the second quarter of 2026 show a net loss attributable to common shareholders of USD 66.97 million and operating cash flow of USD 54.79 million, figures that keep execution and cash conversion central to the next results update.

Natera stock holds near its high

Natera stock was trading at EUR 380.65 at Lang & Schwarz on October 6, 2026 at 11:31 a.m. CEST, plus 0.37 percent versus the Lang & Schwarz prior close of EUR 379.25. Natera is listed on Nasdaq under ticker NTRA, operates in healthcare diagnostics, and had a market capitalization of USD 61.0 billion as of October 5, 2026.